Metamizole Sodium USP FOB Shanghai prices in China increased in April 2026, recording a 1.9% rise from March levels amid stable pharmaceutical export demand and balanced manufacturing conditions. The Metamizole Sodium USP market remained supported by consistent procurement activity from Latin America, Southeast Asia, and African pharmaceutical sectors, where analgesic and antipyretic formulations continued witnessing stable consumption. Chinese manufacturers maintained healthy operating rates due to adequate feedstock availability and manageable utility costs, ensuring uninterrupted Metamizole Sodium USP production and export flow throughout the month. Market sentiment for Metamizole Sodium USP also strengthened moderately due to stable inventories, firm supplier offers, and cautious freight-market conditions linked to rising global shipping surcharges and geopolitical uncertainty surrounding the Middle East. However, buyers largely avoided aggressive spot accumulation and continued focusing on contractual replenishment and operational inventory management. Balanced supply conditions and resilient export demand ultimately allowed Chinese Metamizole Sodium USP suppliers to sustain firmer FOB Shanghai pricing during April 2026.
